Global Strategic Alliance to Deliver Drug Safety Programs
Announced Between AMS Advanced Medical Services GmbH, B&B Clinical Innovations, Inc., and Sentrx. Companies to address growing need for risk management solutions in the pharmaceutical and biotechnology industries

Little Falls, NJ – September 18, 2002 - Sentrx, a provider of leading technological solutions and services for global drug safety and risk management, announced today that it has formed a strategic alliance with AMS Advanced Medical Services GmbH (AMS) and B&B Clinical Innovations, Incorporated (BBCI). AMS and BBCI are Contract Research Organizations dedicated to providing quality, reliability and expertise through comprehensive clinical trial management services. BBCI provides services in North America, while AMS focuses on Western, Central and Eastern European countries.

The alliance brings together the expertise required to meet the demands of risk management and drug safety programs mandated by the FDA and the EMEA. Once a new drug is declared “approvable,” pharmaceutical companies often need to rapidly design a safety registry or postmarketing surveillance program to gain final approval. Patient recruitment across the globe may be required; but unlike typical clinical trials and registries, the key design criterion is safety, not efficacy. By combining the unparalleled depth of pharmacovigilance knowledge at Sentrx with the extensive clinical trial experience of BBCI and AMS, the strategic alliance ensures that pharmaceutical and biotechnology companies can launch new products with a risk management or drug safety program that minimizes safety risks and maximizes benefits to patients.

“This global strategic alliance will provide world-class support and services in our specialized arena,” said Michael Sugerman, Chairman and Chief Executive Officer of Sentrx. “The Sentrx SafetyTrak? Risk Management Solution incorporates advanced technologies into our Safety Response Centers to enable the real-time monitoring and collection of safety-related events and issues across languages and countries. By adding the capabilities of BBCI and AMS, the integrated offering delivers the right infrastructure to manage and perform risk management programs across North America and Europe.”

“I am excited to be part of this global strategic alliance, as drug safety programs are becoming vital to the success of our clients’ new products,“ said Sean Hart, Chief Executive Officer of B&B Clinical Innovations, Inc. “BBCI and AMS have already partnered successfully on several important projects that required a strong presence in both the US and Europe. Sentrx adds the safety technology and specialization needed to address patient registries and postmarketing surveillance programs.“

“AMS has enjoyed a longstanding partnership with BBCI that is based on trusting relationships between people in both companies,” said Christian Carls, MD, PhD, and Chief Executive Officer of AMS Advanced Medical Services GmbH. “We are looking forward to the extension of this relationship with Sentrx, which demonstrates that all three partners are listening to their customers and responding flexibly and quickly to their needs.”

"The combination of Sentrx's unique safety expertise and technologies and BBCI's solid clinical trial experience is precisely what is needed for effective risk management programs,” said Gerald Faich, MD, MPH, former head of drug safety at the FDA, and a member of the Sentrx Board of Directors. “The alliance between these three companies will provide a much needed, powerful and efficient capability to the pharmaceutical industry."

About AMS Advanced Medical Services
AMS offers services and consulting in clinical research as well as in marketing and sales to the pharmaceutical industry worldwide. The company provides Phase I to Phase IV studies and postmarketing surveillance programs in all indications, with AMS Teams that are enthusiastic and committed to efficiency and service. AMS uses innovative techniques, such as e-learning programs combined with face-to-face training for clinical trial investigators, study participants and sales forces. For more information on AMS Advanced Medical Services, please visit the company’s website at www.ams-europe.com.

About B&B Clinical Innovations, Inc.
BBCI is a high-quality, cost-effective Contract Research Organization dedicated to delivering on-time, reliable clinical trial management services to clients around the world. BBCI has been providing quality results in Phase II-IV studies for more than 27 years and has extensive postmarketing surveillance experience in every major therapeutic area, with more than 100,000 patients enrolled in studies during the past five years. More information about B&B Clinical Innovations can be found at www.bbclinical.com, or by calling 1-816-421-6400.

About Sentrx
Sentrx is a provider of leading technological solutions and services for global drug safety and risk management. Its mission is to manage generalized and specific safety risks associated with developing and marketing pharmaceuticals. With multilingual Safety Response Centers in the United States, Europe and Australia, Sentrx delivers a unique combination of highly skilled people, exclusive technology, and best practices in drug safety monitoring. To learn more about Sentrx, please visit their website at www.sentrx.com; send an e-mail to info@sentrx.com; or call 1-888-399-8032, extension 261.

###

Director of Marketing
Sentrx
Overlook at Great Notch
150 Clove Road
Little Falls, NJ 07424
Phone: 973-812-7575 ext. 261
Fax: 973-812-9094
e-Mail: info@sentrx.com 
Website: www.sentrx.com